Subsidy Tracker Parent Company Summary
Parent Company Name:
Pfizer
Ownership Structure:
publicly traded (ticker symbol PFE)
Headquartered in:
New York
Major Industry:
pharmaceuticals
Specific Industry:
pharmaceuticals
| Subsidy Summary | Subsidy Value | Number of Awards |
|---|---|---|
| State/Local | $321,218,841 | 189 |
| Federal (grants and allocated tax credits) | $54,408,698 | 29 |
| TOTAL | $375,627,539 | 218 |
| Loan / Bailout Summary | Total Face Value | Number of Awards |
| State/Local loans, bond financing and venture capital | $220,000,000 | 1 |
| Federal loans, loan guarantees and bailout assistance (not including repayments) | $0 | 0 |
| TOTAL | $220,000,000 | 1 |
Time Period for State and Local Awards:
Earliest year of data: 1992. Availability of data for earlier years varies greatly from program to program. The majority of the listings for this parent company are for the period since 2009.
Time Period for Federal Awards:
FY2000 to the present
Notes:
Dollar totals do not include awards for which no subsidy value is disclosed.
Associated Names:
ALPHARMA SPECIALTY PHARMA; AMERICAN HOME PROD; ANACOR PHARMACEUTICALS; BIOREXIS; DORAL / PFIZER; EMBREX; FOLDRX PHARMACEUTICALS; GD SEARLE; HOSPIRA; ICAGEN; INNOPHARMA; KING PHARMACEUTICALS LLC; KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT; PARKE DAVIS; PARKEDALE PHARMACEUTICALS; PFIZER; PFIZER HOLDING AMERICAS; PHARMACIA; SERENEX; UPJOHN; WARNER LAMBERT; WYETH
Links:
For a summary of this company's regulatory violations see its Violation Tracker summary page here.
For an overview of this company's accountability track record, read its Corporate Rap Sheet here.
For more details on misconduct by this company, see its entry in the Project On Government Oversight's Federal Contractor Misconduct Database.
For a summary of this company's federal contracts, see its page on Fedspending.
For an overview of political contributions associated with this company, see its Follow the Money page.
| Top 5 States for state/local awards | Total Subsidy $ | Number of Awards |
|---|---|---|
| Michigan | $85,200,000 | 2 |
| Connecticut | $60,000,000 | 1 |
| North Carolina | $49,205,269 | 74 |
| New York | $44,472,079 | 26 |
| New Jersey | $38,807,831 | 5 |
| All other | $43,533,662 | 81 |
Individual Subsidy Records:
Click on the company name for more information on each subsidy award.
| Company | Location | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value |
Type of Subsidy |
|---|---|---|---|---|---|---|
| Pfizer, Inc. | North Carolina | state | 2011 | $501,793 | tax credit/rebate | |
| Alpharma Specialty Pharma, Inc. | North Carolina | state | 2012 | $3,885 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2012 | $32,718 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2012 | $54,345 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2012 | $218,644 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2012 | $607,213 | tax credit/rebate | |
| Alpharma, Inc. | West Virginia | state | 2007 | undisclosed | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2010 | $18,433 | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2011 | $49,888 | tax credit/rebate | |
| Pfizer, Inc. | Maryland | state | 2008 | $131,514 | tax credit/rebate | |
| Pfizer Corporation | Maryland | state | 2007 | $123,426 | tax credit/rebate | |
| Pharmacia Corporation | Maryland | state | 2008 | $74,621 | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2012 | $60,651 | tax credit/rebate | |
| Pfizer Inc. | Maryland | state | 2005 | $60,097 | tax credit/rebate | |
| Pfizer, Inc. | Maryland | state | 2009 | $56,291 | tax credit/rebate | |
| Pfizer Inc. | Maryland | state | 2004 | $33,734 | tax credit/rebate | |
| Pharmacia Corporation | Maryland | state | 2007 | $9,773 | tax credit/rebate | |
| Pharmacia Corporation | Maryland | state | 2005 | $4,398 | tax credit/rebate | |
| Pharmacia Corporation | Maryland | state | 2004 | $1,884 | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2014 | $60,651 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2013 | $755,362 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2013 | $272,967 | tax credit/rebate | |
| Pharmacia Corporation | North Carolina | state | 2013 | $145,378 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2013 | $31,549 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2013 | $29,917 | tax credit/rebate | |
| Wyeth Pharmaceuticals, Inc. | North Carolina | state | 2013 | $1,058 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2013 | $261,281 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2013 | $4,097,786 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2013 | $231,735 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2014 | $3,476,438 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2014 | $59,897 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2014 | $5,969 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2014 | $143,193 | tax credit/rebate | |
| Wyeth Pharmaceuticals, Inc. | North Carolina | state | 2013 | $1,058 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2013 | $29,917 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2013 | $31,549 | tax credit/rebate | |
| Pharmacia Corporation | North Carolina | state | 2013 | $145,378 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2013 | $272,967 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2013 | $755,362 | tax credit/rebate | |
| Alpharma Specialty Pharma, Inc. | North Carolina | state | 2012 | $3,885 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2012 | $32,718 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2012 | $54,345 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2012 | $218,644 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2012 | $607,213 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2014 | $218,428 | tax credit/rebate | |
| Wyeth Holdings Corporation | North Carolina | state | 2014 | $143,193 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2014 | $5,969 | tax credit/rebate | |
| Doral/Pfizer | New York | local | 2014 | $607,052 | tax credit/rebate | |
| Wyeth Pharmaceuticals, Inc. | North Carolina | state | 2016 | $3,214 | tax credit/rebate | |
| Wyeth Pharmaceuticals, Inc. | North Carolina | state | 2015 | $3,442 | tax credit/rebate | |
| King Pharmaceuticals Research and Development, Inc. | North Carolina | state | 2016 | $3,809 | tax credit/rebate | |
| King Pharmaceuticals Research and Development, Inc | North Carolina | state | 2015 | $15,133 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2016 | $16,007 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2016 | $25,455 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2016 | $26,647 | tax credit/rebate | |
| Icagen, Inc. | North Carolina | state | 2015 | $60,444 | tax credit/rebate | |
| Embrex, Inc. | North Carolina | state | 2015 | $61,459 | tax credit/rebate | |
| Pfizer Holdings Americas Corporation | North Carolina | state | 2016 | $66,776 | tax credit/rebate | |
| Pfizer Holdings Americas Corporation | North Carolina | state | 2015 | $187,566 | tax credit/rebate | |
| Pfizer Holdings Americas Corporation | North Carolina | state | 2015 | $236,159 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2015 | $240,137 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2016 | $277,903 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2016 | $415,010 | tax credit/rebate | |
| Hospira, Inc. | North Carolina | state | 2015 | $623,585 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2016 | $1,013,383 | tax credit/rebate | |
| Pfizer, Inc. | North Carolina | state | 2015 | $1,320,134 | tax credit/rebate | |
| Doral/Pfizer | New York | local | 2015 | $402,469 | tax credit/rebate | |
| Pfizer Inc., and Subsidiaries | Maryland | state | 2015 | $427,891 | tax credit/rebate | |
| Pfizer, Inc. & Subsidiaries | Maryland | state | 2016 | $79,533 | tax credit/rebate | |
| Pfizer, Inc. | Pennsylvania | state | 2016 | $237,427 | tax credit/rebate | |
| Doral/Pfizer | New York | local | 2016 | $402,469 | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2017 | $183,559 | tax credit/rebate | |
| Pfizer, Inc. | Michigan | state | 2019 | $1,000,000 | tax credit/rebate | |
| Pfizer Inc. & Subsidiaries | Maryland | state | 2018 | $92,193 | tax credit/rebate | |
| Alpharma Inc | West Virginia | state | 2008 | undisclosed | tax credit/rebate | |
| Doral/Pfizer | New York | local | 2003 | $613,020 | tax credit/rebate; property tax abatement | |
| Doral Arrowwood (Pfizer) | New York | local | 2004 | $3,137,110 | tax credit/rebate; property tax abatement | |
| Pfizer, Inc. | New York | local | 2004 | $1,919,713 | tax credit/rebate; property tax abatement | |
| Pfizer, Inc. | New York | local | 2005 | $3,276,473 | tax credit/rebate; property tax abatement | |
| Doral Arrowwood (Pfizer) | New York | local | 2005 | $701,075 | tax credit/rebate; property tax abatement | |
| Pfizer, Inc. | New York | local | 2006 | $3,750,210 | tax credit/rebate; property tax abatement | |
| Doral Arrowwood (Pfizer) | New York | local | 2006 | $2,022,893 | tax credit/rebate; property tax abatement | |
| Pfizer, Inc. | New York | local | 2007 | $5,510,432 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2007 | $662,163 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2009 | $932,710 | tax credit/rebate; property tax abatement | |
| WYETH HOLDINGS CORPORATION | New York | local | 2009 | $280,900 | tax credit/rebate; property tax abatement | |
| Pfizer | New York | local | 2003 | $10,401,000 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2010 | $596,605 | tax credit/rebate; property tax abatement | |
| Pfizer, Inc. | New York | local | 2008 | $862,541 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2008 | $462,392 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2011 | $360,540 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2012 | $357,613 | tax credit/rebate; property tax abatement | |
| Doral/Pfizer | New York | local | 2013 | $516,004 | tax credit/rebate; property tax abatement | |
| HOSPIRA, INC. | California | state | 2006 | $439,595 | training reimbursement | |
| HOSPIRA, INC. | California | state | 2009 | $536,590 | training reimbursement | |
| Hospira, Inc | California | state | 2007 | undisclosed | training reimbursement | |
| PFIZER, INC. | Missouri | state | 2007 | $2,000,000 | training reimbursement | |
| BioRexis | Pennsylvania | state | $250,000 | training reimbursement | ||
| Hospira, Inc. | Kansas | state | 2006 | $68,770 | training reimbursement | |
| Hospira, Inc. | Kansas | state | 2007 | $190,000 | training reimbursement | |
| Hospira Inc. | Colorado | state | 2014 | $31,104 | training reimbursement |
